Bibliographic Details
| Title: |
Reply to: 'Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.' by D. Fabrizio et al. |
| Authors: |
McGrail, D.J.1 djmcgrail@mdanderson.org, Pilié, P.G.2, Rashid, N.U.3,4, Voorwerk, L.5, Slagter, M.6,7,8, Kok, M.5,9, Jonasch, E.2, Khasraw, M.10, Heimberger, A.B.11,12, Ueno, N.T.13, Ferrarotto, R.14, Chang, J.T.15,16, Lin, S.-Y.1 sylin@mdanderson.org |
| Source: |
Annals of Oncology. Sep2021, Vol. 32 Issue 9, p1194-1197. 4p. |
| Database: |
Academic Search Ultimate |
